IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 876-900 out of 1241.

<< < 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 > >>

Public Release: 11-Dec-2013
2013 CTRC-AACR San Antonio Breast Cancer Symposium
Study identifies highly effective treatment option for patients with HER2-positive breast cancer
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 11-Dec-2013
2013 CTRC-AACR San Antonio Breast Cancer Symposium
Exercise protects against aggressive breast cancer in black women
A nearly 20-year observational study involving more than 44,700 black women nationwide found that regular vigorous exercise offers significant protection against development of the most aggressive subtypes of breast cancer. The findings from the Black Women's Health Study are being presented Wednesday, Dec. 11 at the 2013 San Antonio Breast Cancer Symposium.
NIH/National Cancer Institute

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 11-Dec-2013
2013 CTRC-AACR San Antonio Breast Cancer Symposium
Researchers to present event-free and overall survival results from NeoALTTO trial
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14.
GlaxoSmithKline

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 11-Dec-2013
2013 CTRC-AACR San Antonio Breast Cancer Symposium
High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 10-Dec-2013
PLoS Genetics
Researchers describe the key role of a protein in the segregation of genetic material during cell division
Researchers at the Cell Cycle Research Group of the Bellvitge Institute of Biomedical Research led by Ethel Queralt have reported in the journal PLoS Genetics an article which delve into the regulator mechanisms of mitosis, a key stage of the cell-cycle for the correct transmission of genetic information from parents to sons.
Spanish Ministry of Science and Innovation, Catalonian Government Agency AGAU

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 10-Dec-2013
Cell Metabolism
SIRT5 regulation has dramatic effect on mitochondrial metabolism
The Sirtuin family of protein deacylases has received considerable attention due to its links to longevity, diabetes, cancer, and metabolic regulation. In a new study researchers identified widespread regulation of proteins involved in metabolism by the mitochondrial sirtuin, SIRT5. Using a novel method scientists identified hundreds of proteins that undergo modification by lysine succinylation and its subsequent regulation by SIRT5. These findings have widespread implications for understanding metabolic function in both normal and disease states.
National Institutes of Health

Contact: Kris Rebillot
krebillot@buckinstitute.org
415-209-2080
Buck Institute for Age Research

Public Release: 10-Dec-2013
CA: A Cancer Journal for Clinicians
Review calls for increased attention to cancer risk from silica
A new review highlights new developments in understanding the health effects of silica, and calls for action to reduce illness and death from silica exposure at work.

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 10-Dec-2013
Cancer Cell
Scientists shed new light on the fight against cancer
The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response. This is a first. Nrp1 may provide an important hub for the development of new therapies against cancer.

Contact: Kris Van der Beken
kris.vanderbeken@vib.be
0032-924-46611
VIB (the Flanders Institute for Biotechnology)

Public Release: 10-Dec-2013
55th American Society of Hematology Annual Meeting
Drug-antibody pair has promising activity in non-Hodgkin lymphoma
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
Seattle Genetics

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 10-Dec-2013
55th American Society of Hematology Annual Meeting
Less painful drug delivery for pediatric leukemia patients is safe, effective
Children with acute lymphoblastic leukemia, the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.
NIH/National Cancer Institute, Enzon Pharmaceuticals

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute

Public Release: 10-Dec-2013
55th American Society of Hematology Annual Meeting
Blood
ASH late-breaking abstracts offer insights on genetic origins of disease and treatment strategies
A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

Contact: Kassidie Blackstock
Kassidie.Blackstock@fleishman.com
865-776-6827
American Society of Hematology

Public Release: 10-Dec-2013
Science
Danger in disguise: UCLA researchers find brain cancer cells can 'hide' from drugs
Glioblastoma is the most common and deadly form of brain cancer. Drugs target specific mutations on the surface of glioblastoma cells. Glioblastoma cells are able to eliminate the gene mutation to avoid detection when the targeted drug is present. When the drug is stopped, tumor cells are able to reacquire the gene mutation, which resensitizes them to the drug.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 10-Dec-2013
Journal of Clinical Oncology
Game-changing shift occurring in cancer discovery and treatment
Research advances that have come to fruition over the past year demonstrate extraordinary progress in the fight against cancer, according to a new report released today by the American Society of Clinical Oncology. The report stresses, however, that recent budget cuts and years-long flat funding can only delay efforts to translate research into effective treatments for millions of individuals with cancer.

Contact: Susie Tappouni
Susie.Tappouni@asco.org
571-483-1355
American Society of Clinical Oncology

Public Release: 10-Dec-2013
AACR Conference on The Science of Cancer Health Disparities
Researcher finds way to identify aggressive cancers in black women
African-American women who get breast cancer often get more aggressive forms of the disease and at younger ages than other women. But a Georgia State University researcher has found a way to identify these aggressive cancers in black women, which would let their doctors customize their treatment.
National Cancer Institute

Contact: Ann Claycombe
claycombe@gsu.edu
404-413-5047
Georgia State University

Public Release: 10-Dec-2013
Journal of Experimental Therapeutics
Novel agent set for unique clinical test in inflammatory breast cancer
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 10-Dec-2013
Preventative Medicine
Can celebrity cancer diagnoses prompt quitting smoking?
In a study published this week in Preventive Medicine, researchers led by San Diego State University professor John Ayers found that when celebrities publicly discuss their struggles with cancer diagnoses, the resulting media coverage prompts more smokers to search for information on quitting than events like New Year's Day or World No Tobacco Day.
Bloomberg Initiative, Institute for Global Tobacco Control, Johns Hopkins Bloomberg School of Public Health

Contact: Beth Chee
bchee@mail.sdsu.edu
619-594-4563
San Diego State University

Public Release: 10-Dec-2013
Human Genetics
Scientists identify more powerful approach to analyze melanoma's genetic causes
There may be a better way to analyze the genetic causes of cutaneous melanoma according to a study published in Human Genetics conducted by researchers Yale and Dartmouth. A statistical analysis using the natural and orthogonal interaction model showed increased power over existing approaches for detecting genetic effects and interactions when applied to the genome-wide melanoma dataset.
National Institutes of Health

Contact: Donna Dubuc
Donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth

Public Release: 9-Dec-2013
Nature Methods
Measuring life's tugs and nudges
Scientists at Harvard University have devised the first method to measure the forces cells exert on each other in living three-dimensional tissues, including developing embryos. The method, developed at the Wyss Institute for Biological Engineering at Harvard University and the Harvard School of Engineering and Applied Sciences, could lead to new insights into how body shape develops as well as new tools to diagnose cancer, hypertension, connective tissue diseases, and more.

Contact: Dan Ferber
617-432-1547
Wyss Institute for Biologically Inspired Engineering at Harvard

Public Release: 9-Dec-2013
Journal of Cancer Survivorship
Keep on exercising, researchers advise older breast cancer survivors
To build and maintain muscle strength, it is best for older breast cancer survivors to follow an ongoing exercise program of resistance and impact training. This summarizes the findings of a team of researchers who published their study in Springer's Journal of Cancer Survivorship. They found out that the bone benefit from one year of such training could be maintained, even with less exercise, up to a year later.

Contact: Renate Bayaz
renate.bayaz@springer.com
49-622-148-78531
Springer

Public Release: 9-Dec-2013
Neurology
REiNS collaboration seeks common outcome measures for neurofibromatosis clinical trials
As potentially effective new treatments for neurofibromatosis (NF) are developed, standardized research approaches -- including outcome measures specific to NF -- are needed. The first report from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration has been published as a supplement to Neurology®, the Official Journal of the American Academy of Neurology. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 9-Dec-2013
Clinical Cancer Research
Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
Scientists at Rutgers University believe a targeted drug delivery system could make ovarian cancer more treatable for the most deadly gynecological cancer in the United States. In animal research the cancer is attacked at the genetic level by using small, inhibiting RNA molecules that directly target and decrease the excess CD44 protein in cancer cells while simultaneously treating patients with the anti-cancer drug paclitaxel. This allows cells within the cancerous tumors to be successfully treated even at an advanced stage.

Contact: Robin Lally
rlally@ucm.rutgers.edu
732-932-7084 x652
Rutgers University

Public Release: 9-Dec-2013
Cancer Cell
Gene sequencing project finds family of drugs with promise for treating childhood tumor
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the Dec. 9 edition of the scientific journal Cancer Cell.
Pediatric Cancer Genome Project, Kay Jewelers, NIH/National Cancer Institute, Howard Hughes Medical Institute, Tully Family Foundation, American-Lebanese-Syrian Associated Charities

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 9-Dec-2013
Nature Methods
May the cellular force be with you
Like tiny construction workers, cells sculpt embryonic tissues and organs in the 3-D space. This task is complicated and requires constant communication between cells to coordinate their actions and generate the forces that will shape their environment into complex tissue morphologies.

Contact: Sonia Fernandez
sonia.fernandez@ia.ucsb.edu
805-893-4765
University of California - Santa Barbara

Public Release: 9-Dec-2013
Urologic Oncology
Better guidelines, coordination needed for prostate cancer specialists
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to UC Davis prostate cancer experts.

Contact: Dorsey Griffith
dorsey.griffith@ucdmc.ucdavis.edu
916-734-9118
University of California - Davis Health System

Public Release: 9-Dec-2013
Cancer Cell
Genetic flaw in males triggers onset of liver cancer, diabetes
Michigan State University researchers have uncovered a genetic deficiency in males that can trigger the development of one of the most common types of liver cancer and forms of diabetes.
National Institute of Health

Contact: Sarina Gleason
sarina.gleason@cabs.msu.edu
517-355-9742
Michigan State University

Showing releases 876-900 out of 1241.

<< < 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 > >>

  Search News Releases

     

 

 

EurekAlert!